|Day Low/High||19.60 / 20.65|
|52 Wk Low/High||6.17 / 19.76|
Insiders at these companies have been scooping up shares in their own organizations lately.
Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.
Investors eyeing a purchase of Versartis Inc stock, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $10 strike, which has a bid at the time of this writing of $1.35.
Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Biotechnology stocks can be risky but it's helpful to track them over time.
The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 352,820 share decrease in total short interest for Versartis Inc , to 974,210, a decrease of 26.59% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Total of 137 patients enrolled; top-line results expected in Q3 2017
Enrollment to be Complete by Mid-August in the Phase 3 VELOCITY Trial for Pediatric GHD; Data Expected Q3 2017
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.